Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000669857 | SCV000794649 | uncertain significance | Neuronal ceroid lipofuscinosis 2 | 2017-10-12 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001844216 | SCV002103470 | uncertain significance | not specified | 2022-02-09 | criteria provided, single submitter | clinical testing | Variant summary: TPP1 c.457T>C (p.Ser153Pro) results in a non-conservative amino acid change located in the Peptidase S53, activation domain (IPR015366) of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 251460 control chromosomes (gnomAD). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.457T>C has been reported in the literature in one French family affected with Neuronal Ceroid-Lipofuscinosis (Batten Disease) (example: Mole_2001, Gardner_2019). These data do not allow any conclusion about variant significance. One publication reports structural evidence evaluating an impact on protein structure, suggesting it disturbs normal processing of the TPP1 precursor protein (Pal_2009). One ClinVar submitter has assessed the variant since 2014: the variant was classified as of uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. |